Wave Life Sciences prices upsized $200M public offering of ordinary shares and pre-funded warrants

Wave Life Sciences Ltd.

Offering of 23.1M ordinary shares at $8.00/share and 1.9M pre-funded warrants at $7.9999 each; gross proceeds ~$200M.
Underwriters have 30-day option to purchase up to an additional 3.75M ordinary shares on same terms.
Offering expected to close on or about Sept 27, 2024; cash runway extended into 2027 excluding GSK/Takeda milestones.
Following close, pro forma ordinary shares outstanding expected to be approximately 148.4M.
J.P. Morgan and Leerink Partners acting as joint book-running managers; Truist and Mizuho as book-runners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.